ATAI Investor Day Presentation Deck

Positive Developments. FDA clearly recognizes the severity of the unmet need and continues to be open to expediting CIAS drug development programs. The potential economic gain to society for a successful treatment of CIAS is enormous and likely to be welcomed by private and government payors.

View entire presentation